Free shipping on all orders over $ 500

Patritumab

Cat. No. M24595

All AbMole products are for research use only, cannot be used for human consumption.

Patritumab Structure
Synonym:

Human Anti-ERBB3 Recombinant Antibody

Size Price Availability Quantity
100ug USD 190  USD190 In stock
1mg USD 400  USD400 In stock
5mg USD 800  USD800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab , potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.

Immobilized human HER3 His at 2 ug/mL can bind patritumab, EC50=0.04264 ug/mL.

Human HER3 HEK293 cells were stained with patritumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2297 ug/mL.

Chemical Information
Molecular Weight 146860
CAS Number 1262787-83-6
Storage Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles.
References

[1] Kumiko Koyama, et al. PLoS One. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drυg conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression

[2] Sun Min Lim, et al. Cancer Discov. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

[3] Kimio Yonesaka, et al. Clin Cancer Res. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

[4] Pasi A Jänne, et al. Cancer Discov. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

[5] Hidehito Horinouchi. Expert Opin Biol Ther. The prospect of patritumab for treating non-small cell lung cancer

Related EGFR/HER2 Products
Depatuxizumab

Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR.

Sevabertinib

Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.

BPIQ-I

BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor..

HKI-357 

HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively.

SJF-1528 

SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells.

  Catalog
Abmole Inhibitor Catalog




Keywords: Patritumab, Human Anti-ERBB3 Recombinant Antibody supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.